Popular Trials
Alkylating agents
Chemotherapy + Radiation for Kidney Cancer (Wilms' Tumor)
Recruiting2 awardsPhase 3
Royal Oak, Michigan
This trial is studying how well combo chemo with or without radiation therapy works to treat young patients newly diagnosed with stage III or stage IV Favorable Histology Wilms' tumor.
Alkylating agents
Chemotherapy + Stem Cell Transplant for Brain Cancer
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
This trial is studying two different chemotherapy combinations to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma.
Popular Filters
Phase 3 Trials
Radiation
Radiation + Chemotherapy for Medulloblastoma
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is looking at whether standard-dose radiation therapy, versus reduced-dose, is more effective in children 3-7 years of age who have had surgery for newly diagnosed standard-risk medulloblastoma.
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
Recruiting4 awardsPhase 3
Washington, District of Columbia
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Trials With No Placebo
Anti-metabolites
Decitabine for Myelofibrosis
Recruiting1 awardPhase 2
Fort Wayne, Indiana
This trial looks at the side effects and effectiveness of decitabine in treating patients with myelofibrosis, a cancer of the blood system. Decitabine may block proteins that turn certain genes off in various cancers including myelofibrosis.
Radiation
Radiation + Chemotherapy for Medulloblastoma
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is looking at whether standard-dose radiation therapy, versus reduced-dose, is more effective in children 3-7 years of age who have had surgery for newly diagnosed standard-risk medulloblastoma.
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Fort Wayne, Indiana
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.